COGT
NASDAQCogent Biosciences Inc.
Price$32.40+0.91 (+2.88%)
01:30 PM04:15 PM
News · 26 weeks43-50%
2025-12-142026-06-07
Mix1990d
- Other11(58%)
- SEC Filings4(21%)
- Insider3(16%)
- Analyst1(5%)
Latest news
25 items- PRCogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual MeetingBezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p<0.0001) for bezuclastinib combination compared to sunitinib alone Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib Priority Review granted following FDA acceptance of NDA for bez
- PRCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GISTNDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30, 2026 Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against an active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p<0.0001) for bezuclastinib combination compared to sunitinib alone Full results from the Phase 3 PEAK trial to be shared in oral presentation at ASCO on Saturday, May 30, 2026 WALTHAM, Mass. and BOULDER, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NA
- PRCogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare ConferenceWALTHAM, Mass. and BOULDER, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 11:05 a.m. ET. A live webcast will be available on the Investors & Media page of Cogent's website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days. Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Cogent also announced today that, on May 26, 2
- INSIDERPresident and CEO Robbins Andrew R received a gift of 160,000 shares and gifted 160,000 shares, decreasing direct ownership by 24% to 497,503 units (SEC Form 4)4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.SCHEDULE 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)
- PRCogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 CongressPivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent's third oral presentation of pivotal data with bezuclastinib at major medical meetings Preclinical data from selective, potent JAK2 V617F program accepted for poster presentation WALTHAM, Mass. and BOULDER, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two presentations from the company's Advanced Systemic Mastocytosis (AdvSM) program, including an oral presentation highlighting the results of the APEX trial, as well as a poster presentation
- SECSEC Form 10-Q filed by Cogent Biosciences Inc.10-Q - Cogent Biosciences, Inc. (0001622229) (Filer)
- SECCogent Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cogent Biosciences, Inc. (0001622229) (Filer)
- PRCogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation at 2026 ASCO annual meeting - Ended 1Q 2026 with $866.4 million in cash, sufficient to fund operations into 2028 WALTHAM, Mass. and BOULDER, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2026. "2026 is shaping up to be a pivotal year for Cogent," said And
- SECSEC Form DEFA14A filed by Cogent Biosciences Inc.DEFA14A - Cogent Biosciences, Inc. (0001622229) (Filer)
- SECSEC Form DEF 14A filed by Cogent Biosciences Inc.DEF 14A - Cogent Biosciences, Inc. (0001622229) (Filer)
- PRCogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingWALTHAM, Mass. and BOULDER, Colo., April 21, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the results from the Phase 3 PEAK trial have been selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL, May 29-June 2, 2026. The presentation will feature data from the positive trial of bezuclastinib in combination with sunitinib in patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib. Top line results were reported in November 2025, and t
- PRCogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026– Updated presentation on Cogent's potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors – Updated presentation on Cogent's brain penetrant ErbB2 inhibitor, CGT4255, with evidence of synergistic activity in combination with HER2 ADCs for resistant patients WALTHAM, Mass. and BOULDER, Colo., April 17, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that preclinical data from the Company's KRAS and ErbB2 pipeline programs will be presented during poster se
- INSIDERSEC Form 4 filed by Ferrante Karen Jean4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
- PRCogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination demonstrated 16.5 month mPFS and 46% ORR in imatinib-resistant GIST patients, dramatically improving upon the current standard of care WALTHAM, Mass. and BOULDER, Colo., April 01, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastin
- INSIDERSEC Form 4 filed by Fairmount Funds Management Llc4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.SCHEDULE 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)
- ANALYSTJefferies resumed coverage on Cogent BiosciencesJefferies resumed coverage of Cogent Biosciences with a rating of Buy
- PRCogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)WALTHAM, Mass. and BOULDER, Colo., March 16, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2026. In addition, the FDA communicated that at this time, there is no plan to hold an advisory committee, nor have they identified any potential review issues.Clinical results from the pivotal SUMMIT trial wit
- PRCogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual MeetingBezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with 83% rate of normalizationStrong evidence of bezuclastinib's potential as first disease modifying agent for NonAdvSM patient population given clear correlation between objective measures of disease burden and symptomatic improvement WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional clinica
- SECSEC Form S-8 filed by Cogent Biosciences Inc.S-8 - Cogent Biosciences, Inc. (0001622229) (Filer)
- SECSEC Form 10-K filed by Cogent Biosciences Inc.10-K - Cogent Biosciences, Inc. (0001622229) (Filer)
- SECCogent Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cogent Biosciences, Inc. (0001622229) (Filer)
- PRCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsSUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026PEAK NDA initiated for bezuclastinib in patients with 2L GIST under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD); completion of NDA on track for April 2026Six abstracts from SUMMIT trial of bezuclastinib in patients with NonAdvSM accepted for presentation at 2026 AAAAI annual meetingStrong financial position with $901 million sufficient to fund operations into 2028 WALTHAM, Mass. and BOULDER, Colo., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company f
- PRCogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual MeetingWALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced multiple upcoming posters highlighting bezuclastinib results from the SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients at the 2026 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in Philadelphia, PA, February 27-March 2, 2026. In December 2025, Cogent announced that the company submitted its New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration. The submission is based on posi
COGT FAQ
7 questionsWhat does Cogent Biosciences Inc. do?
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly...Where does COGT stock trade?
Cogent Biosciences Inc. (COGT) is listed on NASDAQ.What sector and industry is COGT in?
Cogent Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cogent Biosciences Inc. go public?
Cogent Biosciences Inc. (COGT) completed its IPO in 2018.What are analysts saying about COGT?
Cogent Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2026-03-16. Recent price targets range from $800.00 to $4000.00.What companies are similar to COGT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare COGT side-by-side with any of them on Quantisnow.How can I track COGT on Quantisnow?
Quantisnow aggregates Cogent Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow COGT to receive live email and push alerts on every new disclosure.